Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.

Date publication

décembre 2019

Journal

United European gastroenterology journal

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Pantavou K, Yiallourou AI, Piovani D, Evripidou D, Danese S, Peyrin-Biroulet L, Bonovas S, Nikolopoulos GK

Lien Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/31839954

Résumé

Ulcerative colitis (UC) is an inflammatory disease of the colon and rectum. Treatment options include biologics and tofacitinib.

Mots clés

adverse effect, anti-TNF, efficacy, inflammatory bowel disease, serious adverse effect, small molecule, ulcerative colitis

Référence

United European Gastroenterol J. 2019 Dec;7(10):1285-1303